| Gene symbol | RAF1 | Synonyms | CMD1NN, CRAF, NS5, Raf-1, c-Raf | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3p25.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | Raf-1 proto-oncogene, serine/threonine kinase | ||||
| GTO ID | GTC1188 |
| Trial ID | NCT00024648 |
| Disease | Neoplasm |
| Altered gene | RAF1 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | LErafAON |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | Phase I Study to Determine the Maximum Tolerated Dose of LErafAON in Combination With Radiotherapy in Patients With Advanced Malignancies |
| Year | 2001 |
| Country | United States |
| Company sponsor | INSYS Therapeutics Inc |
| Other ID(s) | LErafAON-001 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||